Beta Bionics Beats Q4 Estimates, Sets 2026 Guidance With Pharmacy-Channel Targets

Overview

• Q4 2025 results: $32.1 million in revenue, up 57.1% year over year, with a net loss of $13.5 million or 38¢ per share.
• Results topped Wall Street forecasts, with revenue exceeding the $31.1 million consensus and EPS beating by 8¢.
• The installed base reached 35,011 users, up 129% year over year, as Q4 new patient starts rose 37% to 5,592.
• 2026 outlook calls for $130–$135 million in revenue, gross margin of 55.5%–57.5%, and 36%–38% of new starts reimbursed through the pharmacy benefit plan channel.
• R&D updates include completion of a first-in-human Phase 2a feasibility trial for the bihormonal program and a Mint patch pump targeted for 2027, while shares rose about 1% after hours to $14.10.